Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of CORLUX™ (Mifepristone) in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
NCT00130676 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of CORLUX™ (Mifepristone) in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
- Lead sponsor
- Corcept Therapeutics
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 30, 2004
- Completion date
- June 30, 2006
- Enrollment
- 257 (actual)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.